NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 100 | -73.3% | 0.00% | – |
| Q2 2023 | $0 | -100.0% | 374 | -97.0% | 0.00% | – |
| Q1 2023 | $8,000 | -90.0% | 12,344 | -65.4% | 0.00% | – |
| Q4 2022 | $80,000 | +60.0% | 35,702 | +128.7% | 0.00% | – |
| Q3 2022 | $50,000 | +56.2% | 15,614 | +86.4% | 0.00% | – |
| Q2 2022 | $32,000 | -57.3% | 8,378 | -39.8% | 0.00% | – |
| Q1 2022 | $75,000 | +36.4% | 13,917 | +245.7% | 0.00% | – |
| Q4 2021 | $55,000 | -81.0% | 4,026 | -75.0% | 0.00% | – |
| Q3 2021 | $290,000 | +19.8% | 16,127 | +14.5% | 0.00% | – |
| Q2 2021 | $242,000 | +120.0% | 14,087 | +155.7% | 0.00% | – |
| Q1 2021 | $110,000 | -60.9% | 5,509 | -66.7% | 0.00% | – |
| Q4 2020 | $281,000 | +37.7% | 16,529 | +34.6% | 0.00% | – |
| Q3 2020 | $204,000 | -46.5% | 12,280 | -25.4% | 0.00% | – |
| Q2 2020 | $381,000 | -59.1% | 16,466 | -68.5% | 0.00% | – |
| Q1 2020 | $932,000 | +150.5% | 52,241 | +203.6% | 0.00% | – |
| Q4 2019 | $372,000 | -69.7% | 17,207 | -74.5% | 0.00% | – |
| Q3 2019 | $1,229,000 | -44.9% | 67,487 | +7.7% | 0.00% | -100.0% |
| Q2 2019 | $2,230,000 | +22.5% | 62,687 | +15.7% | 0.00% | 0.0% |
| Q1 2019 | $1,821,000 | +98.4% | 54,185 | +94.1% | 0.00% | – |
| Q4 2018 | $918,000 | -26.5% | 27,913 | +36.2% | 0.00% | -100.0% |
| Q3 2018 | $1,249,000 | +94.5% | 20,500 | +55.8% | 0.00% | – |
| Q2 2018 | $642,000 | -93.9% | 13,157 | -86.8% | 0.00% | -100.0% |
| Q1 2018 | $10,597,000 | +7362.7% | 99,728 | +4106.2% | 0.01% | – |
| Q4 2017 | $142,000 | -59.8% | 2,371 | -83.9% | 0.00% | – |
| Q3 2017 | $353,000 | +667.4% | 14,706 | +524.2% | 0.00% | – |
| Q2 2017 | $46,000 | -87.5% | 2,356 | -85.0% | 0.00% | – |
| Q1 2017 | $369,000 | +74.1% | 15,743 | -8.4% | 0.00% | – |
| Q4 2016 | $212,000 | +1666.7% | 17,187 | +2472.9% | 0.00% | – |
| Q3 2016 | $12,000 | -96.4% | 668 | -97.2% | 0.00% | – |
| Q2 2016 | $336,000 | -84.0% | 23,606 | -84.6% | 0.00% | – |
| Q1 2016 | $2,104,000 | +345.8% | 152,934 | +446.6% | 0.00% | – |
| Q4 2015 | $472,000 | -11.1% | 27,980 | -42.2% | 0.00% | – |
| Q3 2015 | $531,000 | -19.5% | 48,420 | -8.1% | 0.00% | – |
| Q2 2015 | $660,000 | +23.8% | 52,707 | +8.9% | 0.00% | – |
| Q1 2015 | $533,000 | -32.1% | 48,420 | -4.3% | 0.00% | -100.0% |
| Q4 2014 | $785,000 | +34.6% | 50,589 | +4.8% | 0.00% | – |
| Q3 2014 | $583,000 | -41.7% | 48,270 | -38.1% | 0.00% | -100.0% |
| Q2 2014 | $1,000,000 | +4.6% | 77,970 | -1.1% | 0.00% | 0.0% |
| Q1 2014 | $956,000 | +664.8% | 78,858 | +616.9% | 0.00% | – |
| Q4 2013 | $125,000 | +19.0% | 11,000 | +8.9% | 0.00% | – |
| Q3 2013 | $105,000 | -37.1% | 10,100 | -29.9% | 0.00% | – |
| Q2 2013 | $167,000 | – | 14,399 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |